Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A sterile **ophthalmic combination small-molecule drug product** containing bacitracin zinc, neomycin sulfate, polymyxin b sulfate, and hydrocortisone acetate. The three anti-infective components provide broad antibacterial coverage against common ocular pathogens, while hydrocortisone acetate is a corticosteroid that suppresses inflammatory responses and reduces ocular edema and irritation. It is indicated for **steroid-responsive inflammatory ocular conditions** where superficial bacterial infection is present or a risk of bacterial infection exists, including inflammatory conditions of the conjunctiva, cornea, and anterior segment of the globe, chronic anterior uveitis, infective conjunctivitis, and corneal injury from chemical, radiation, or thermal burns or foreign-body penetration. The product is marketed as an ophthalmic ointment and is available as branded and generic formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacitracin zinc + neomycin sulfate + hydrocortisone acetate + polymyxin b.